Redcare Pharmacy appoints Peter Schmid as CEO: Redcare Pharmacy stock gains 2.25 percent

Published on 10/16/2026 at 09:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Guidance targets 16 to 18 percent after 56 percent Q3 Rx growth. Redcare Pharmacy stock costs EUR 74.95 on October 16, 2026 versus EUR 73.30 Xetra close.

Leadership and growth markers

Peter Schmid von Linstow became CEO effective October 14, 2026.
Full-year 2026 revenue growth guidance rose to 16 to 18 percent on September 28, 2026.
Redcare Pharmacy stock trades at EUR 74.95 at 9:36 a.m. CEST at Lang & Schwarz on October 16, 2026, 2.25 percent above the Xetra close of October 15, 2026.
Redcare Pharmacy will publish its third-quarter interim statement on October 29, 2026.

Makroaufnahme von weißen unbeschrifteten Tabletten und Kapseln mit dramatischem Licht — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, zeigt Makroaufnahme markenfreier weißer Tabletten und Kapseln mit Streiflicht, Illustration mit AI erstellt.

Redcare Pharmacy (ISIN NL0012044747) was trading at EUR 74.95 at Lang & Schwarz on October 16, 2026, at 9:36 a.m. CEST, up 2.25 percent versus the Xetra close of October 15, 2026 at EUR 73.30. Simply Wall St reported that Peter Schmid von Linstow became a new Managing Board member and CEO effective October 14, 2026.

Leadership arrives before results

The CEO change gives Redcare Pharmacy a leadership transition just before its next quarterly update. Schmid von Linstow brings more than 20 years of international leadership experience in digital platforms and marketplaces, including roles at Visable, Parship, eBay and AutoScout24, according to Simply Wall St. The appointment places digital execution and customer acquisition alongside the company's prescription-drug growth story.

Three milestones shape the story

On July 30, 2026, Redcare reported second-quarter revenue of EUR 853.5 million, up 20 percent from the prior-year quarter, while net income fell 50 percent to EUR 4.70 million, according to Simply Wall St. On September 28, 2026, Redcare raised full-year revenue growth guidance to 16 to 18 percent from 15 to 17 percent, while German prescription revenue guidance rose to EUR 730 million to EUR 760 million from EUR 680 million to EUR 720 million, according to Redcare Pharmacy. On October 14, 2026, Schmid von Linstow took over as CEO with more than 20 years of platform experience.

What does the guidance mean for margins?

The growth upgrade has not yet changed the profitability corridor. Redcare confirmed an adjusted EBITDA margin of 2.5 to 3.0 percent for full-year 2026, while preliminary German prescription revenue grew 56 percent in the third quarter and 51 percent in September year over year, according to Redcare Pharmacy. That combination makes the October report important: investors will see whether faster prescription growth is translating into operating leverage.

Next dates are already set

Redcare Pharmacy will publish its third-quarter 2026 interim statement and host its quarterly conference call on October 29, 2026. The company has also scheduled its 2026 annual report for March 4, 2027, according to Redcare Pharmacy.

Stock stays below the yearly high

At EUR 74.95, the stock remains EUR 14.55 below its EUR 89.50 52-week high as of October 16, 2026. The share was trading at EUR 74.95 at Lang & Schwarz on October 16, 2026 at 9:36 a.m. CEST, 2.25 percent above the Xetra close of October 15, 2026 at EUR 73.30. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.